Kern Medical Center Foundation

Kern Medical Foundation continues to steward funds from the $9.2m received from California health facilities authority for Kern Medical pediatrics inpatient and outpatient renovation.kern Medical Foundation, on behalf of Kern Medical, was awarded $46,000 for equity and practice transformation from the department of health care services.american cancer society awarded $10,000 to Kern Medical Foundation to help support Kern Medical oncology patients and provide transportation and lodging assistance to patients with needs.kern medial Foundation received $120,000 from ca bridge program to support substance use and mat navigation services to patients in the emergency department at Kern medical.kern Medical Foundation, on behalf of Kern Medical, was awarded $3m from Kern health systems to support provider recruitment and retention, healthcare workforce expansion and quality grant program that will enhance the quality of care delivered to members with the goal of increasing preventative health services and closing gaps in care. Kern Medical Foundation continued to receive $200,000 from the cdc for valey fever education and awareness through our cooperative agreement; improving clinical and public health outcomes through national partnerships to prevent and control emerging and re-emerging infectious disease threats.kern Medical Foundation, on behalf of the valley fever institute at Kern Medical, was awarded a subaward agreement under a u19 research grant with ucla. Enrollment in host immunogenetics and fungal virulence mechanisms in coccidioidomycosis started in 2022 and will continue through 2027.kern Medical Foundation, on behalf of the valley fever institute at Kern Medical, was awarded a subaward agreement with uc davis to for a retrospective study of patients treated with cresemba for valley fever.kern Medical Foundation, on behalf of the valley fever institute at Kern Medical, enrolled in a clinical trial of a novel antifungal; olorofim for treatment of invasive fungal infections (ifi) due to moulds in patients with limited or no treatment options: interim results from a phase 2b open-label study (nct03583164, study 32).kern Medical Foundation, on behalf of the valley fever institute at Kern Medical, continued to provide administrative oversight for an nih research study; an observational study to assess the prevalence and outcomes of primary pulmonary coccidioidomycosis (sands-ppc).kern Medical Foundation, on behalf of the valley fever institute at Kern Medical, solicited and was awarded a contract with the cdc to provide serum specimens from valley fever patients for a biobank.